![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Three Breast Cancer Drugs Pose Risks of Lung Inflammation, FDA Says
Three Breast Cancer Drugs Pose Risks of Lung Inflammation, FDA Says
![WarningTape.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/WarningTape.gif?t=1576815636&width=430)
September 20, 2019
The FDA warned of rare but severe lung inflammation risks for Pfizer’s Ibrance (palbociclib), Novartis’ Kisqali (ribociclib) and Eli Lilly’s Verzenio (abemaciclib), three treatments for advanced breast cancer.
The agency said the benefit of the drugs is “still greater than the risks when used as prescribed,” but it approved new warnings about the lung inflammation risks for the prescribing information and patient package inserts.
Possible symptoms include difficult or uncomfortable breathing, as well as shortness of breath while resting or during low physical activity, the agency said.
Upcoming Events
-
21Oct